Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | CTSK | P43235 | 6/20 | 0.51 |
| ▸ | CTSL | P07711 | 5/20 | 0.50 |
| ▸ | CTSB | P07858 | 3/20 | 0.50 |
| ▸ | CTSS | P25774 | 3/20 | 0.50 |
| ▸ | PPARA | Q07869 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CASP1 | P29466 | 2/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25907874 | 1.00 | SYK (0.54) | SYKALDH1A1ALOX15CTSKCTSL | |
| SCHEMBL14295020 | 0.92 | CTSL (0.53) | SYKCTSKCTSLCTSBCTSS | |
| SCHEMBL21876533 | 0.92 | CTSL (0.53) | SYKCTSKCTSLCTSBCTSS | |
| SCHEMBL11165466 | 0.92 | CTSL (0.53) | SYKCTSKCTSLCTSBCTSS | |
| SCHEMBL2776833 | 0.92 | PPARA (0.55) | SYKCTSKCTSLCTSBCTSS | |
| SCHEMBL5971174 | 0.92 | PPARA (0.55) | SYKCTSKCTSLCTSBCTSS | |
| SCHEMBL42877 | 0.92 | PPARA (0.55) | SYKCTSKCTSLCTSBCTSS | |
| SCHEMBL9819558 | 0.92 | SYK (0.55) | SYKALDH1A1ALOX15CTSKCTSL | |
| SCHEMBL29336406 | 0.92 | SYK (0.55) | SYKALDH1A1ALOX15CTSKCTSL | |
| SCHEMBL13570899 | 0.92 | SYK (0.55) | SYKALDH1A1ALOX15CTSKCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912644-B2 | Processes for the preparation of (S)-tert-butyl 4,5-diamino-5-oxopentanoate | CELGENE CORPORATION (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230234914-A1 | PROCESSES FOR THE PREPARATION OF (S)-TERT-BUTYL 4,5-DIAMINO-5-OXOPENTANOATE | CELGENE CORPORATION | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234914-A1 | PROCESSES FOR THE PREPARATION OF (S)-TERT-BUTYL 4,5-DIAMINO-5-OXOPENTANOATE | UMPS, DHPS, NT5C3B | SYK 2358/4885ALDH1A1 1398/4885ALOX15 1195/4885 |
| US-11912644-B2 | Processes for the preparation of (S)-tert-butyl 4,5-diamino-5-oxopentanoate | UMPS, DHPS, NT5C3B | SYK 2358/4885ALDH1A1 1398/4885ALOX15 1195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.